Camurus today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiztm (CAM2029), octreotide ...
Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...
Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Stocktwits on MSN
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial
The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in ...
Crinetics Pharmaceuticals shares gained after the company reported positive results from its Phase 2 study of atumelnant as a treatment for congenital adrenal hyperplasia. The stock was up 9.4% to $51 ...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shares rallied 19% after the company reported a strong early commercial ...
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December ...
Viatris Inc. (NASDAQ:VTRS) also reported that the Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted its ...
This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...
In patients with normal GH suppression and increased IGF-1 levels after surgery, IGF-1 normalized within 3 to 5 years without additional treatment. Individuals with acromegaly who have discordant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback